|Videos|September 9, 2022
The future of ibrexafungerp for prevention of recurrent yeast infections
Author(s)Morgan Ebert
Nkechi Azie, MD, MBA, FIDSA, vice president of clinical development and medical affairs at SCYNEXIS, discusses the potential FDA approval of ibrexafungerp (Brexafemme; SCYNEXIS) for the prevention of recurrent vulvovaginal candidiasis.
Advertisement
Note: BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp. Most common adverse reactions observed in clinical trials (incidence ≥2%) were diarrhea, nausea, abdominal pain, dizziness, and vomiting.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
When to refer bladder symptoms in ob-gyn practice—and why young age is not reassuring
2
Mark Simon, MD, MMM, on the OB hospitalist care model
3
Contraception counseling is essential at GLP-1 RA initiation in reproductive-age patients
4
Addressing Cognitive Symptoms and Transitioning from MHT to Non-Hormonal Therapy for VMS
5